Overview
U.S. agtech firm's Q4 revenue declined yr/yr and missed analyst expectations
Net loss narrowed per share, aided by cost reduction initiatives
Company raised $22.3 mln in January 2026 to support operations and commercialization efforts
Outlook
Cibus targets commercial launch of Rice traits in LATAM in 2027 and USA in 2028
Company expects additional scale-up orders for bio-fragrances in second half of 2026
Cibus aims to reduce annual net cash usage to $30 mln or less during 2026
Result Drivers
COST REDUCTION INITIATIVES - Co said lower R&D and SG&A expenses in Q4 were primarily due to cost reduction initiatives
SUSTAINABLE INGREDIENTS PROGRAM - Co received its first customer payment from the Sustainable Ingredients program in Q4, marking a commercial milestone
ASSET IMPAIRMENT - Co recorded a $9.1 mln non-cash impairment charge related to winding down its Roseville, Minnesota facility
Company press release: ID:nGNX9qtKKQ
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue | Miss | $1.06 mln | $1.64 mln (3 Analysts) |
Q4 EPS | -$0.59 | ||
Q4 Net Income | -$31.95 mln | ||
Q4 Income from Operations | -$22.57 mln | ||
Q4 Operating Expenses | $23.63 mln | ||
Q4 Pretax Profit | -$31.94 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Cibus Inc is $16.00, about 349.4% above its March 16 closing price of $3.56
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)